The control group was patients without cirrhosis Pneumonia

The control group was patients without cirrhosis. Pneumonia

vaccination was defined as receiving a single dose of Pneumovax at any point of time during the study period. Results The control group had 855450 adults and the liver cirrhosis group had 10430 patients. A total of 27 % of the patients in the liver cirrhosis group had the Pneumovax compared to 22 % in the control group (P <0.001). In patients older than 65 only 36 % had the Pneumovax in the cirrhosis group compared to 53 % in the no cirrhosis group (P <0.001). Conclusion To date this is the largest study evaluating up take of Pneumovax in the cirrhosis population. Despite the well-known benefit of the Pneumovax the prevalence of vaccination in patients with cirrhosis is dramatically low, especially in over 65's, although it is better than the general population, overall. Renewed vigor needs to be maintained in educating patients and physicians on Seliciclib cell line the importance of vaccinating cirrhosis CDK activation patients Data presented as N (column %) with Pearson’s chi-square. Disclosures: Naim Alkhouri – Advisory

Committees or Review Panels: Gilead Sciences The following people have nothing to disclose: Tuyyab Hassan, Sulieman Abdal Raheem, Ripple Mehta, Omer J. Deen, Annette Kyprianou Background and Objective: New treatments offer greater potential to cure chronic hepatitis C viral (HCV) infection than ever before; however access to therapy is limited by subop-timal screening and the number of providers trained in HCV care. The Department of Health and Human Services has identified the need to build a workforce of providers capable of managing this website patients with

HCV infection; however, physicians often participate in education that reinforces what they already know versus that which addresses their true educational needs. This study evaluated the effectiveness of an online, personalized learning curriculum on improving physicians’ performance in HCV care. Methods: An online, case-based self-assessment (SA) was used to identify physicians’ individual practice gaps in the care of patients with HCV. Each SA question mapped to 1 of 5 practice gaps, each of which, in turn, corresponded to a distinct online CME intervention. Each physician was directed to one or more relevant CME interventions based on individual educational needs identified through the results of their SA. Each CME intervention included post-assessment questions matched to questions from the SA. Educational effectiveness was measured through statistical comparison between the SA and post-assessment data. Results: Initial data (November 19, 2013-March 06, 2014) reveal significant improvements from baseline with respect to: ▪ Recognizing the rationale for birth cohort screening (gastroenterologists, n=24: 33% vs 75%, P=.02; PCPs, n=174: 37% vs 52%, P=.02) ▪ Ordering the appropriate test to confirm HCV infection (PCPs, n=212: 79% vs 94%, P< .

The control group was patients without cirrhosis Pneumonia

The control group was patients without cirrhosis. Pneumonia

vaccination was defined as receiving a single dose of Pneumovax at any point of time during the study period. Results The control group had 855450 adults and the liver cirrhosis group had 10430 patients. A total of 27 % of the patients in the liver cirrhosis group had the Pneumovax compared to 22 % in the control group (P <0.001). In patients older than 65 only 36 % had the Pneumovax in the cirrhosis group compared to 53 % in the no cirrhosis group (P <0.001). Conclusion To date this is the largest study evaluating up take of Pneumovax in the cirrhosis population. Despite the well-known benefit of the Pneumovax the prevalence of vaccination in patients with cirrhosis is dramatically low, especially in over 65's, although it is better than the general population, overall. Renewed vigor needs to be maintained in educating patients and physicians on selleck inhibitor the importance of vaccinating cirrhosis LY2157299 nmr patients Data presented as N (column %) with Pearson’s chi-square. Disclosures: Naim Alkhouri – Advisory

Committees or Review Panels: Gilead Sciences The following people have nothing to disclose: Tuyyab Hassan, Sulieman Abdal Raheem, Ripple Mehta, Omer J. Deen, Annette Kyprianou Background and Objective: New treatments offer greater potential to cure chronic hepatitis C viral (HCV) infection than ever before; however access to therapy is limited by subop-timal screening and the number of providers trained in HCV care. The Department of Health and Human Services has identified the need to build a workforce of providers capable of managing click here patients with

HCV infection; however, physicians often participate in education that reinforces what they already know versus that which addresses their true educational needs. This study evaluated the effectiveness of an online, personalized learning curriculum on improving physicians’ performance in HCV care. Methods: An online, case-based self-assessment (SA) was used to identify physicians’ individual practice gaps in the care of patients with HCV. Each SA question mapped to 1 of 5 practice gaps, each of which, in turn, corresponded to a distinct online CME intervention. Each physician was directed to one or more relevant CME interventions based on individual educational needs identified through the results of their SA. Each CME intervention included post-assessment questions matched to questions from the SA. Educational effectiveness was measured through statistical comparison between the SA and post-assessment data. Results: Initial data (November 19, 2013-March 06, 2014) reveal significant improvements from baseline with respect to: ▪ Recognizing the rationale for birth cohort screening (gastroenterologists, n=24: 33% vs 75%, P=.02; PCPs, n=174: 37% vs 52%, P=.02) ▪ Ordering the appropriate test to confirm HCV infection (PCPs, n=212: 79% vs 94%, P< .

5 patients were in situ carcinoma (TiS), 13 were T1-stage cancer,

5 patients were in situ carcinoma (TiS), 13 were T1-stage cancer, and 6 had recurrent esophageal cancer. PDT with different outputs (630 nm wavelength, 260–2000 mW of power, energy dose of 120–400 J/cm) according to the patient’s state was initiated. Therapy response, recurrence rate, survival outcome, and complication of the patients were evaluated. The follow-up period ranged from 2 to 95 months. Results: 21 cases were treated with Photofirn, 3 with photogem, 2 with Photodin, 4 with radachlorin and 2 with ALA. Sensitizer types showed no difference

in complete response (CR) rate or complications. The CR rate was 62.5% (15 of 24) in patients who received PDT. The CR rate was statistically higher (p = 0.027) for patients who had Tis/T1 lesion (14 of 18; 77%) learn more than for those with recurrence (1 of 6; 16%). There was one patient that had recurrence

12 months after PS-341 cost PDT. The survival time was statistically higher (P = 0.003) for patients who had Tis/T1 lesion (86 months) than for those with recurrent tumors (32 months). We experienced six cases of esophageal stenosis (25%) that required dilatation and one case of esophageal perforation (4%) that required operation after PDT. Conclusion: The role of PDT in recurred esophageal cancer is limited, but PDT might be an effective regimen for early esophageal cancer, with overall favorable survival time, and low recurrence rates. Key Word(s): 1. Photodynamic therapy; 2. Esophageal cancer; Presenting Author: ENQIANG LINGHU Additional Authors: ZHICHU QIN Corresponding Author: ENQIANG LINGHU click here Affiliations: Department of Gastroenterology and Hepatology, the

Chinese PLA General Hospitall; Department of Gastroenterology and Hepatology, the PLA General Hospital Objective: This animal study was performed to explore the feasibility and safety of endoscopic transesophageal biopsy using submucosal tunneling technology and novel homemade instruments in the posterior mediastinum. Methods: In 3 survival pigs, a mid-esophageal mucosal incision was performed and a 10-cm submucosal tunnel was developed with blunt dissection. The endoscope attached to homemade decompression tube was passed through the muscular layers into the posterior mediastinal space. The mediastinal compartment, lung, thoracic duct, vagus nerves, and exterior surface of the esophagus were identified. Mediastinal living tissue as lymph node biopsy was accomplished. During two survival weeks, blood test and temperature monitoring and chest radiograph and endoscopic examination were performed. Results: The procedure was performed successfully in all pigs. Mediastinal structures could be identified without difficulty though the transesophageal tunneling approach. Living tissue as lymph node and pleural biopsy under direct visualization was feasible. One pig died after operation due to an unexplained pneumothorax.

5 patients were in situ carcinoma (TiS), 13 were T1-stage cancer,

5 patients were in situ carcinoma (TiS), 13 were T1-stage cancer, and 6 had recurrent esophageal cancer. PDT with different outputs (630 nm wavelength, 260–2000 mW of power, energy dose of 120–400 J/cm) according to the patient’s state was initiated. Therapy response, recurrence rate, survival outcome, and complication of the patients were evaluated. The follow-up period ranged from 2 to 95 months. Results: 21 cases were treated with Photofirn, 3 with photogem, 2 with Photodin, 4 with radachlorin and 2 with ALA. Sensitizer types showed no difference

in complete response (CR) rate or complications. The CR rate was 62.5% (15 of 24) in patients who received PDT. The CR rate was statistically higher (p = 0.027) for patients who had Tis/T1 lesion (14 of 18; 77%) learn more than for those with recurrence (1 of 6; 16%). There was one patient that had recurrence

12 months after ATM/ATR targets PDT. The survival time was statistically higher (P = 0.003) for patients who had Tis/T1 lesion (86 months) than for those with recurrent tumors (32 months). We experienced six cases of esophageal stenosis (25%) that required dilatation and one case of esophageal perforation (4%) that required operation after PDT. Conclusion: The role of PDT in recurred esophageal cancer is limited, but PDT might be an effective regimen for early esophageal cancer, with overall favorable survival time, and low recurrence rates. Key Word(s): 1. Photodynamic therapy; 2. Esophageal cancer; Presenting Author: ENQIANG LINGHU Additional Authors: ZHICHU QIN Corresponding Author: ENQIANG LINGHU click here Affiliations: Department of Gastroenterology and Hepatology, the

Chinese PLA General Hospitall; Department of Gastroenterology and Hepatology, the PLA General Hospital Objective: This animal study was performed to explore the feasibility and safety of endoscopic transesophageal biopsy using submucosal tunneling technology and novel homemade instruments in the posterior mediastinum. Methods: In 3 survival pigs, a mid-esophageal mucosal incision was performed and a 10-cm submucosal tunnel was developed with blunt dissection. The endoscope attached to homemade decompression tube was passed through the muscular layers into the posterior mediastinal space. The mediastinal compartment, lung, thoracic duct, vagus nerves, and exterior surface of the esophagus were identified. Mediastinal living tissue as lymph node biopsy was accomplished. During two survival weeks, blood test and temperature monitoring and chest radiograph and endoscopic examination were performed. Results: The procedure was performed successfully in all pigs. Mediastinal structures could be identified without difficulty though the transesophageal tunneling approach. Living tissue as lymph node and pleural biopsy under direct visualization was feasible. One pig died after operation due to an unexplained pneumothorax.

RASA1 protein expression in HCT116 with upregulated miR-21 was si

RASA1 protein expression in HCT116 with upregulated miR-21 was significantly lower than that in those with downregulated miR-21. The ability of proliferation in HCT116, RKO with upregulated miR-21 was enhanced over time and vice versa. Conclusion: RASA1 can be a promising molecular target for therapeutic intervention in patients with colon cancer. Key Word(s): 1. miR-21; 2. RASA1; 3. colon cancer; 4. KRAS; Presenting Author: PING DU Additional Authors: NINGNING CONG,

FAJUAN SHEN, QINGYU ZHANG, CHUNSHENG KANG Corresponding Author: QINGYU Selleckchem AZD1208 ZHANG, CHUNSHENG KANG Affiliations: Department of Gastroenterology, General Hospital of Tianjin Medical University; Laboratory of Neuro-oncology, Tian jin Neurological Institute Objective: Wnt/β-catenin signaling pathway is widely studied in many tumors including gastric cancer, which is a leading cause of death in China. Gastric adenocarcinoma is the most common type of gastric cancer. When Wnt/β-catenin signaling pathway is activated, the combination of β-catenin and T-cell factor / Lymphoid enhancer-binding factor (TCF/LEF) is necessary for the expression downstream factors

such as c-Myc and cyclin-D1. We use β-catenin/Tcf inhibitor FH535 to observe its effect on proliferation and invasion of gastric adenocarcinoma cell line SGC-7901 in vivo and in vitro. Methods: Human gastric adenocarcinoma SGC-7901 cells and human glioblastoma LN229 cells were treated with 20 μmol/L FH535 and solvent DMSO for 48 h respectively. BKM120 purchase The cell cycle and apoptosis of treated cells were analyzed by flow cytometry. The invasive ability of SGC-7901 and LN-229 cells was determined by Transwell assay. We also used wound healing test to evaluate the cell migrating ability. Western-blot was used to find the malignancy related protein alteration. Subcutaneous tumor xenograft model was adopted to detect the influence of FH535 on SGC-7901 cell in vivo. 0.3 mg FH535 was delivered to each mice via intraperitoneal

injection every two days. FH535 was totally injected 6 times. Curve of tumor growth was plotted to describe the proliferation of SGC-7901 cell in vivo. Immunohistochemistry analysis and TUNEL this website staining were carried out to evaluate the apoptosis and proliferation state of SGC-7901 cells in vivo. Results: The experiments shows that the group treated with FH535 had significantly higher percentage of cells blocked at G0/G1 phase, lower percentage of cell cloning, less trans-membrane cell numbers, lower migrating rate after 48 h than the other groups. Protein levels of cyclin-D1 and c-Myc decreased in the FH535 group. While there was no significant difference on the percentage of apoptotic cells between the FH535 group and the others. The tumor from FH535 group grew slower than the other two groups. Immunohistochemistry analysis showed higher level of caspase-3 and lower level of Proliferating Cell Nuclear Antigen (PCNA) in the tumor tissue from FH535 group.

Of the 6208 people cared for, 102 (745% type 3, 176% type 2 and

Of the 6208 people cared for, 102 (74.5% type 3, 17.6% type 2 and 7.8% type 1) were under treatment with prophylaxis. learn more The most frequent indications for prophylaxis were joint (40%), epistaxis/oral (23%), GI bleeding (14%) and menorrhagia (5%). Considering countries where prophylaxis is common in VWD, there are reasons to believe that it would benefit a much larger proportion of people than that found in the survey. The VWD PN will, through the VWD International Prophylaxis (VIP) study, address prophylaxis with prospective and retrospective studies in cohorts with, primarily, type 3 VWD, although the

population for consideration for prospective study entry also includes those with type 1 if ≤20% VWF:RCo and/or ≤20% FVIII, and DDAVP MAPK inhibitor non-responsive; type 2 if DDAVP non-responsive, or type 2B who have defined patterns

of gastrointestinal bleeding, joint bleeding, epistaxis or menorrhagia. The objectives of the VIP study are as follows: Identify subjects with VWD who may benefit from prophylaxis. Fifty patients will be enrolled in each bleeding indication group. The prospective study is a non-randomized, dose-escalation investigation where intervals are shortened according to the bleeding pattern. At the first level, 50 U of VWF:RCo per kg will be administered once weekly, at the second level twice weekly, and at the third level three times per week. The dose for women enrolled in the menorrhagia study see more group will escalate from 50 U VWF:RCo per kg on day 1 of menses, to treatment on days 1 and 2 and to treatment on days 1, 2 and 3. This schedule was chosen as the pharmacokinetics of FVIII differ from those seen after infusion of FVIII in haemophilia because of the endogenous release

of FVIII after infusion of VWF which gives a more sustained FVIII level [4]. This dosing approach has a potential to be even more efficacious than experienced in haemophilia [5]. Any product licensed for treatment of VWD may be used. As of February 2010, 18 centres (10 in Europe and 8 in North America) are recruiting patients and an additional 40 centres are preparing for or evaluating participation. Conclusions  The VIP study, within the framework of the VWD PN, will provide evidence-based guidelines for the use of prophylaxis in patients with VWD and frequent bleeding who are not responsive to or eligible for treatment with DDAVP. Summary  In absence of randomized prospective studies for most RBDs, guidelines for prophylaxis are a matter of controversy. It seems logical that in case of a strong family history of bleeding, long-term primary prophylaxis is administered in selected cases of severe RBD. Furthermore, primary prophylaxis limited in time could also be given before some surgeries or during pregnancy, especially for some severe deficiencies associated with pregnancy loss. When recurrent severe bleeds occur in a particular patient, secondary prophylaxis could be discussed.

Of the 6208 people cared for, 102 (745% type 3, 176% type 2 and

Of the 6208 people cared for, 102 (74.5% type 3, 17.6% type 2 and 7.8% type 1) were under treatment with prophylaxis. selleck screening library The most frequent indications for prophylaxis were joint (40%), epistaxis/oral (23%), GI bleeding (14%) and menorrhagia (5%). Considering countries where prophylaxis is common in VWD, there are reasons to believe that it would benefit a much larger proportion of people than that found in the survey. The VWD PN will, through the VWD International Prophylaxis (VIP) study, address prophylaxis with prospective and retrospective studies in cohorts with, primarily, type 3 VWD, although the

population for consideration for prospective study entry also includes those with type 1 if ≤20% VWF:RCo and/or ≤20% FVIII, and DDAVP selleck products non-responsive; type 2 if DDAVP non-responsive, or type 2B who have defined patterns

of gastrointestinal bleeding, joint bleeding, epistaxis or menorrhagia. The objectives of the VIP study are as follows: Identify subjects with VWD who may benefit from prophylaxis. Fifty patients will be enrolled in each bleeding indication group. The prospective study is a non-randomized, dose-escalation investigation where intervals are shortened according to the bleeding pattern. At the first level, 50 U of VWF:RCo per kg will be administered once weekly, at the second level twice weekly, and at the third level three times per week. The dose for women enrolled in the menorrhagia study check details group will escalate from 50 U VWF:RCo per kg on day 1 of menses, to treatment on days 1 and 2 and to treatment on days 1, 2 and 3. This schedule was chosen as the pharmacokinetics of FVIII differ from those seen after infusion of FVIII in haemophilia because of the endogenous release

of FVIII after infusion of VWF which gives a more sustained FVIII level [4]. This dosing approach has a potential to be even more efficacious than experienced in haemophilia [5]. Any product licensed for treatment of VWD may be used. As of February 2010, 18 centres (10 in Europe and 8 in North America) are recruiting patients and an additional 40 centres are preparing for or evaluating participation. Conclusions  The VIP study, within the framework of the VWD PN, will provide evidence-based guidelines for the use of prophylaxis in patients with VWD and frequent bleeding who are not responsive to or eligible for treatment with DDAVP. Summary  In absence of randomized prospective studies for most RBDs, guidelines for prophylaxis are a matter of controversy. It seems logical that in case of a strong family history of bleeding, long-term primary prophylaxis is administered in selected cases of severe RBD. Furthermore, primary prophylaxis limited in time could also be given before some surgeries or during pregnancy, especially for some severe deficiencies associated with pregnancy loss. When recurrent severe bleeds occur in a particular patient, secondary prophylaxis could be discussed.

4) The AUC of the model that combined IL28B genotype and serum I

4). The AUC of the model that combined IL28B genotype and serum IP-10

(AUC 0.80) clearly outperformed the models based on the individual variables, including the model based on IL28B genotype alone (AUC 0.70). The addition of race and baseline viral load further improved the model, although the added gain was modest (AUC up to 0.85). This is the first study to combine the highly useful IL28B genotype with baseline IP-10 levels to demonstrate an independent and additive model for predicting SVR with PEG-IFN and ribavirin treatment. We demonstrated that low pretreatment Quizartinib in vivo serum IP-10 is associated with SVR in both CA and AA HCV genotype 1 patients from the VIRAHEP-C cohort. Using pretreatment serum IP-10 (above or below 600 pg/mL) as a predictive biomarker for treatment response in our cohort revealed a positive predictive value of 69% and a negative predictive value of 67%. These results are in line with other studies, confirming that pretreatment IP-10 is lower in patients who subsequently achieve SVR on therapy compared with nonresponder patients.15-20 The prognostic use of baseline IP-10 levels has also been confirmed in other difficult-to-treat populations, such as patients coinfected with HCV and human immunodeficiency virus15 and patients

with an elevated viral load and body mass index.18 The current study greatly extends the potential clinical use DAPT of IP-10 and refines the predictive value of IL28B gene polymorphisms. Based on five genome-wide association studies, single nucleotide polymorphisms predictive of both spontaneous and treatment-induced viral clearance in HCV genotype 1 have been identified near the IL28B gene.21, 24-27 Carriage of a C allele at the IL28B gene polymorphism (rs12979860)

is favorably associated with treatment response to PEG-IFN and ribavirin in both AA and CA patients.21 This was confirmed in our VIRAHEP-C check details cohort with SVR rates of 87% with CC, 50% with CT, and 39% with TT genotypes. Most striking, stratification by high or low baseline IP-10 (above or below 600 pg/mL) further improved the predictability of SVR among the genotype groups, especially in IL28B T allele carriers. Multivariate analysis confirmed that IL28B genotype and baseline IP-10 levels are independent and additive predictors of HCV treatment response. Likewise, in a predictive model of SVR, serum IP-10 can be used as a dynamic variable, which complements the static IL-28B genotype and further individualizes treatment response. The polymorphisms on chromosome 19 associated with HCV treatment response are in the region that encodes the IFN-λ genes (IL28A, IL28B, and IL29). The IL28B gene encodes IFN-λ3, which has a unique signaling receptor as well as a common downstream signaling system with type I IFNs.22, 23 The role of IFN-λ in control of multiple viral infections, including HCV, is currently under study.

Methods: A total of 50 patients undergoing computed tomography (C

Methods: A total of 50 patients undergoing computed tomography (CT) and endoscopic ultrasonography (EUS) at our institute were included in this study. CE-EUS was performed when mural lesions were detected on EUS. The ability to diagnose the presence of mural nodules with each imaging modality was evaluated. In addition, the measurement accuracy of the height of mural nodules with

each imaging modality was compared. Results: Resection was performed in 17 cases, with the remaining 33 patients placed Selleck MAPK Inhibitor Library under a follow-up of more than 12 months. Of the 17 patients undergoing surgery, the histopathological findings revealed 14 cases with mural nodules and three cases without. When using EUS alone, the rate of accurately diagnosing mural nodules was 72%, but this increased to 98% when using EUS combined with CE-EUS. In terms of the measurement accuracy of the height of mural nodules, CE-EUS performed significantly better than CT find more or EUS (P < 0.05). Using receiver operating characteristic

curve analysis and determining the cut-off value for mural nodule height measured on CE-EUS as 8.8 mm facilitated the accuracy for diagnosing malignant BD-IPMN of 94%. Conclusion: CE-EUS can be used not only to diagnose the presence of mural nodules, but also as an accurate means of measuring the height of mural nodules. Furthermore, using CE-EUS to measure the height of mural nodules provides a highly precise means of determining the difference between benign and malignant BD-IPMN. Key Word(s): 1. contrast-enhanced endoscopic ultrasonography; 2. branch duct intraductal papillary mucinous neoplasm Presenting Author: XIANGYI

HE Additional Authors: YAOZONG YUAN Corresponding Author: XIANGYI HE Affiliations: Ruijin Hospital Objective: EGFR tyrosine kinase inhibitor erlotinib is shown to be promising therapy in combination of gemcitabine in pancreatic cancer. selleck screening library K-RAS mutation is frequently present in pancreatic cancer and is related to anti-EGFR therapy resistance. Our previous study showed DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA. The aim of this study is to evaluate whether silence of DJ-1 can increase anti-EGFR therapy efficiency in pancreatic cancer. Methods: Anti-DJ-1 shRNA and negative control shRNA (nc) was stably transfected into BxPC-3 cell (BxPC3/DJ-1 and BxPC3/NC). BxPC3/DJ-1 and BxPC3/NC shRNA were treated with various doses of erlotinib, and then cell proliferation was measured by CCK-8, Brdu incorporation.

Methods: A total of 50 patients undergoing computed tomography (C

Methods: A total of 50 patients undergoing computed tomography (CT) and endoscopic ultrasonography (EUS) at our institute were included in this study. CE-EUS was performed when mural lesions were detected on EUS. The ability to diagnose the presence of mural nodules with each imaging modality was evaluated. In addition, the measurement accuracy of the height of mural nodules with

each imaging modality was compared. Results: Resection was performed in 17 cases, with the remaining 33 patients placed FK228 in vivo under a follow-up of more than 12 months. Of the 17 patients undergoing surgery, the histopathological findings revealed 14 cases with mural nodules and three cases without. When using EUS alone, the rate of accurately diagnosing mural nodules was 72%, but this increased to 98% when using EUS combined with CE-EUS. In terms of the measurement accuracy of the height of mural nodules, CE-EUS performed significantly better than CT DAPT datasheet or EUS (P < 0.05). Using receiver operating characteristic

curve analysis and determining the cut-off value for mural nodule height measured on CE-EUS as 8.8 mm facilitated the accuracy for diagnosing malignant BD-IPMN of 94%. Conclusion: CE-EUS can be used not only to diagnose the presence of mural nodules, but also as an accurate means of measuring the height of mural nodules. Furthermore, using CE-EUS to measure the height of mural nodules provides a highly precise means of determining the difference between benign and malignant BD-IPMN. Key Word(s): 1. contrast-enhanced endoscopic ultrasonography; 2. branch duct intraductal papillary mucinous neoplasm Presenting Author: XIANGYI

HE Additional Authors: YAOZONG YUAN Corresponding Author: XIANGYI HE Affiliations: Ruijin Hospital Objective: EGFR tyrosine kinase inhibitor erlotinib is shown to be promising therapy in combination of gemcitabine in pancreatic cancer. selleck chemicals llc K-RAS mutation is frequently present in pancreatic cancer and is related to anti-EGFR therapy resistance. Our previous study showed DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA. The aim of this study is to evaluate whether silence of DJ-1 can increase anti-EGFR therapy efficiency in pancreatic cancer. Methods: Anti-DJ-1 shRNA and negative control shRNA (nc) was stably transfected into BxPC-3 cell (BxPC3/DJ-1 and BxPC3/NC). BxPC3/DJ-1 and BxPC3/NC shRNA were treated with various doses of erlotinib, and then cell proliferation was measured by CCK-8, Brdu incorporation.